RxDoctor Payments Data

Sabrina Brana, MD

Internal Medicine · Camarillo, CANPI 1790137388

Payments from drug & device makers

$1,342in general payments, 2019–2025

Across 55 payments — averaging $24.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$256
  • Lilly USA, LLC$159
  • Pfizer$137
  • Abbott$127
  • Novo Nordisk$125
  • Amgen$117
  • plus $419 from 9 others

What the payments were for

  • Food & beverage$1,342100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,342 in reported general payments places this provider in the 75th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$149,802
Medicare patients
234
Services billed
1,510

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide91$111,569
OzempicSemaglutide22$23,252
RybelsusSemaglutide13$22,777
Xigduo XrDapaglifloz Propaned/Metformin16$22,248
XareltoRivaroxaban26$21,839
Trelegy ElliptaFluticasone/Umeclidin/Vilanter31$18,744
JardianceEmpagliflozin14$18,146
EliquisApixaban12$8,065
Dapagliflozin-Metformin ErDapaglifloz Propaned/Metformin12$5,972
Atorvastatin Calcium152$1,742
Lidocaine15$1,641
Levothyroxine Sodium88$1,624
Pantoprazole Sodium63$1,129
Lantus SolostarInsulin Glargine,hum.Rec.Anlog12$1,045
Omeprazole36$1,002

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$159$111,56991 claims
Novo NordiskOzempic, Rybelsus$125$46,02935 claims
GSKTrelegy Ellipta$21$18,74431 claims
Boehringer IngelheimJardiance$38$18,14614 claims
PfizerEliquis$137$8,06512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Camarillo

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →